Header Logo

Connection

Ana Batista to Humans

This is a "connection" page, showing publications Ana Batista has written about Humans.
Connection Strength

0.132
  1. Batista AR. Gene Therapy for Huntington's Disease: The Future Is in Gene Editing. Hum Gene Ther. 2022 Jan; 33(1-2):12-13.
    View in: PubMed
    Score: 0.028
  2. Batista AR, Flotte TR. In?vivo gene editing works in humans: Results of a phase 1 clinical trial for TTR amyloidosis. Mol Ther. 2021 09 01; 29(9):2633-2634.
    View in: PubMed
    Score: 0.028
  3. Batista AR, Sena-Esteves M, Saraiva MJ. Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model. Biochim Biophys Acta. 2013 Aug; 1832(8):1183-93.
    View in: PubMed
    Score: 0.015
  4. Iwanowicz A, Boudi A, Seeley C, Sapp E, Miller R, Liu S, Chase K, Shing K, Batista AR, Siena-Esteves M, Aronin N, DiFiglia M, Kegel-Gleason KB. Intrastriatal Delivery of a Zinc Finger Protein Targeting the Mutant HTT Gene Allele Obviates Lipid Phenotypes in Brain and Plasma in Huntington's Disease?Mice. Hum Gene Ther. 2025 Aug; 36(15-16):1083-1094.
    View in: PubMed
    Score: 0.009
  5. Torres NL, Batista AR, Sousa J, Folia V, Baltos D, Mesquita A, Silva S. Adults With Dyslexia Use Internalised Beat Cues Less Than?Controls When Estimating Interval Length. Dyslexia. 2025 Feb; 31(1):e70001.
    View in: PubMed
    Score: 0.009
  6. Roy AJ, Leipprandt JR, Patterson JR, Stoll AC, Kemp CJ, Oula ZD, Mola T, Batista AR, Sortwell CE, Sena-Esteves M, Neubig RR. AAV9-Mediated Intrastriatal Delivery of GNAO1 Reduces Hyperlocomotion in Gnao1 Heterozygous R209H Mutant Mice. J Pharmacol Exp Ther. 2024 07 18; 390(2):250-259.
    View in: PubMed
    Score: 0.008
  7. Lek A, Wong B, Keeler A, Blackwood M, Ma K, Huang S, Sylvia K, Batista AR, Artinian R, Kokoski D, Parajuli S, Putra J, Carreon CK, Lidov H, Woodman K, Pajusalu S, Spinazzola JM, Gallagher T, LaRovere J, Balderson D, Black L, Sutton K, Horgan R, Lek M, Flotte T. Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy. N Engl J Med. 2023 09 28; 389(13):1203-1210.
    View in: PubMed
    Score: 0.008
  8. Gross AL, Gray-Edwards HL, Bebout CN, Ta NL, Nielsen K, Brunson BL, Lopez Mercado KR, Osterhoudt DE, Batista AR, Maitland S, Seyfried TN, Sena-Esteves M, Martin DR. Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis. Brain. 2022 04 18; 145(2):655-669.
    View in: PubMed
    Score: 0.007
  9. Flotte TR, Cataltepe O, Puri A, Batista AR, Moser R, McKenna-Yasek D, Douthwright C, Gernoux G, Blackwood M, Mueller C, Tai PWL, Jiang X, Bateman S, Spanakis SG, Parzych J, Keeler AM, Abayazeed A, Rohatgi S, Gibson L, Finberg R, Barton BA, Vardar Z, Shazeeb MS, Gounis M, Tifft CJ, Eichler FS, Brown RH, Martin DR, Gray-Edwards HL, Sena-Esteves M. AAV gene therapy for Tay-Sachs disease. Nat Med. 2022 02; 28(2):251-259.
    View in: PubMed
    Score: 0.007
  10. Taghian T, Marosfoi MG, Puri AS, Cataltepe OI, King RM, Diffie EB, Maguire AS, Martin DR, Fernau D, Batista AR, Kuchel T, Christou C, Perumal R, Chandra S, Gamlin PD, Bertrand SG, Flotte TR, McKenna-Yasek D, Tai PWL, Aronin N, Gounis MJ, Sena-Esteves M, Gray-Edwards HL. A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna. Mol Ther. 2020 02 05; 28(2):411-421.
    View in: PubMed
    Score: 0.006
  11. Macedo B, Magalh?es J, Batista AR, Saraiva MJ. Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. Pharmacol Res. 2010 Dec; 62(6):514-22.
    View in: PubMed
    Score: 0.003
  12. Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta. 2008 Sep; 1782(9):517-22.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.